[1]孔德进,孔祥斌,张景秀,等.降脂药与儿童自身免疫性疾病因果关系的药物靶向孟德尔随机化研究[J].医学信息,2025,38(03):91-96.[doi:10.3969/j.issn.1006-1959.2025.03.017]
　KONG Dejin,KONG Xiangbin,ZHANG Jingxiu,et al.Drug-targeted Mendelian Randomization Study on the Causal Relationship Between Lipid-lowering Drugs and Autoimmune Diseases in Children[J].Journal of Medical Information,2025,38(03):91-96.[doi:10.3969/j.issn.1006-1959.2025.03.017]
点击复制

降脂药与儿童自身免疫性疾病因果关系的药物靶向孟德尔随机化研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年03期
页码:
91-96
栏目:
论著
出版日期:
2025-02-01

文章信息/Info

Title:
Drug-targeted Mendelian Randomization Study on the Causal Relationship Between Lipid-lowering Drugs and Autoimmune Diseases in Children
文章编号:
1006-1959（2025）03-0091-06
作者:
孔德进1; 孔祥斌2; 张景秀1; 高 阳1
临沂市中心医院儿科1，耳鼻喉科2，山东 临沂 276400
Author(s):
KONG Dejin1;  KONG Xiangbin2;  ZHANG Jingxiu1;  GAO Yang1
Department of Pediatric1, Department of Otolaryngology2, Linyi Central Hospital, Linyi 276400, Shandong, China
关键词:
降血脂药; 自身免疫疾病; 3-羟基-3-甲基戊二酰辅酶A还原酶; 前蛋白转化酶枯草溶菌素9; 载脂蛋白B类
Keywords:
Lipid-lowering drugs;  Autoimmune diseases;  3-hydroxy-3-methylglutaryl coenzyme A reductase;  Proprotein convertase subtilisin/kexin 9;  Apolipoprotein B
分类号:
R593.2
DOI:
10.3969/j.issn.1006-1959.2025.03.017
文献标志码:
A
摘要:
目的 分析影响降脂药物靶点表达或功能的遗传变异是否与儿童自身免疫性疾病风险相关。方法 使用HMGCR（编码他汀类药物的靶点）、PCSK9（编码PCSK9抑制剂的靶点）和APOB（编码米泊美生的靶点）降脂药物的蛋白靶点编码基因的变异体进行孟德尔随机化分析。使用药物靶点孟德尔随机化（MR）分析靶向抑制剂对不同自身免疫性疾病的影响。结果 抑制HMGCR靶点的表达对儿童1型糖尿病保护作用[IVW法：OR（95%CI）=0.5996（0.3714~0.8277），P=1.11×10-5；加权中位数法：OR（95%CI）=0.6555（0.3725~0.9385），P=0.0034]。抑制APOB靶点对幼年特发性关节炎[IVW法：OR（95%CI）=0.3053（-0.3960~1.0066），P=9.130×10-4；加权中位数法：OR（95%CI）=0.3599（-0.5955~1.3152），P=0.0036]和早发型重症肌无力[IVW法：OR（95%CI）=0.2361（-0.4439~0.9162），P=3.182×10-5；加权中位数法：OR（95%CI）=0.3192（-0.5376~1.1760），P=0.0090]有保护作用。APOB抑制剂对儿童甲状腺炎在IVW法有保护作用[OR（95%CI）=0.3849（-0.5495~1.3193），P=0.0452]，加权中位法无统计学意义[OR（95%CI）=0.3821（-0.6843~1.4485），P=0.0770]。抑制PCSK9、HMGCR和APOB靶点与川崎病、乳糜泻和银屑病的风险均无显著相关性。结论 降脂药可能通过靶点对儿童1型糖尿病、幼年特发性关节炎、早发型重症肌无力及儿童甲状腺炎有保护作用，但临床应用仍需谨慎。
Abstract:
Objective To analyze whether genetic variations affecting the expression or function of lipid-lowering drug targets are associated with the risk of autoimmune diseases in children. Methods Mendelian randomization analysis was performed using HMGCR (encoding the target of statins), PCSK9 (encoding the target of PCSK9 inhibitors), and APOB (encoding the target of milpometasone). Mendelian randomization (MR) was used to analyze the effects of targeted inhibitors on different autoimmune diseases. Results Inhibition of HMGCR target expression had a protective effect on type 1 diabetes mellitus in children [IVW method: OR(95%CI)=0.5996(0.3714-0.8277), P=1.11×10-5; weighted median method: OR(95%CI)=0.6555(0.3725-0.9385)，P=0.0034]. Inhibition of APOB targets had a protective effect on adolescent idiopathic arthritis [IVW method: OR(95%CI)=0.3053(-0.3960-1.0066), P=9.130×10-4; weighted median method: OR(95%CI)=0.3599(-0.5955-1.3152), P=0.0036]and early-onset myasthenia gravis [IVW method: OR(95%CI)=0.2361(-0.4439-0.9162), P=3.182×10-5; weighted median method: OR(95%CI)=0.3192(-0.5376-1.1760)，P=0.0090]. APOB inhibitor had a protective effect on children’s thyroiditis in IVW method [OR(95%CI)=0.3849(-0.5495-1.3193), P=0.0452], and there was no statistical significance in weighted median method [OR(95%CI)=0.3821(-0.6843-1.4485), P=0.0770]. Inhibition of PCSK9, HMGCR, and APOB targets was not significantly associated with the risk of Kawasaki disease, celiac disease, and psoriasis. Conclusion Lipid-lowering drugs may have protective effects on children with type 1 diabetes mellitus, adolescent idiopathic arthritis, early-onset myasthenia gravis and thyroiditis in children through targets, but clinical application still needs to be cautious.

参考文献/References:

[1]Davidson A,Diamond B.Autoimmune diseases[J].N Engl J Med,2001,345(5):340-350.[2]李永柏.自身免疫性疾病概念及临床特征[J].中国实用儿科杂志,2003,2(5):65-67.[3]Slominski RM,Tuckey RC,Manna PR,et al.Extra-adrenal glucocorticoidbiosynthesis:implications for autoimmune and inflammatory disorders[J].Genes Immun,2020,21(3):150-168.[4]Fugger L,Jensen LT,Rossjohn J.Challenges,Progress,and Prospects of Developing Therapies to Treat Autoimmune Diseases[J].Cell,2020,181(1):63-80.[5]Pan L,Liu J,Liu C,et al.Childhood-onset systemic lupus erythematosus:characteristics and the prospect of glucocorticoid pulse therapy[J].Front Immunol,2023,14(6):1128754-1125764.[6]郝胜,黄文彦,曾华松.小分子靶向JAK抑制剂在儿童风湿免疫性疾病中的应用[J].中国实用儿科杂志,2021,36(11):853-857.[7]Kotyla PJ,Islam MA,Engelmann M.Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis[J].Int J Mol Sci,2020,21(19):25-37.[8]Campos-López B,Meza-Meza MR,Parra-Rojas I,et al.Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients:A cross-sectional study[J].Clin Immunol,2021,222(4):108637-108649.[9]Hamad ARA,Sadasivam M,Rabb H.Hybrid lipids,peptides,and lymphocytes:new era in type 1 diabetes research[J].J Clin Invest,2019,12(9):9-25.[10]Robinson G,Pineda-Torra I,Ciurtin C,et al.Lipid metabolism in autoimmune rheumatic disease:implications for modern and conventional therapies[J].J Clin Invest,2022,132(2):125-132.[11]Wroński A,G?誰gotek A,Skrzydlewska E.Protein adducts with lipid peroxidation products in patients with psoriasis[J].Redox Biol,2023,63(5):102729-102737.[12]Lei Q,Yang J,Li L,et al.Lipid metabolism and rheumatoid arthritis[J].Front Immunol,2023,14(5):119060-119074.[13]Müller-Calleja N,Hollerbach A,Royce J,et al.Lipid presentation by the protein C receptor links coagulation with autoimmunity[J].Science,2021,371(6534):1121-1136.[14]Wang C,Yosef N,Gaublomme J,et al.CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity[J].Cell,2015,163(6):1413-1427.[15]Sniderman AD,Thanassoulis G,Glavinovic T,et al.Apolipoprotein B Particles and Cardiovascular Disease:A Narrative Review[J].JAMA Cardiol,2019,4(12):1287-1295.[16]Li Z,Tian M,Jia H,et al.Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk:a Mendelian randomization study[J].Amyotroph Lateral Scler Frontotemporal Degener,2023,3(5):1-10.[17]Lou C,Meng Z,Shi YY,et al.Genetic association of lipids and lipid-lowering drugs with sepsis:aMendelian randomization and mediation analysis[J].Front Cardiovasc Med,2023,10(8):1217922-1217933.[18]Xie W,Li J,Du H,et al.Causal relationship between PCSK9 inhibitor and autoimmune diseases:a drug target Mendelian randomization study[J].Arthritis Res Ther,2023,25(1):148-160.[19]Williams DM, Finan C, Schmidt AF,et al.Lipid lowering and Alzheimer disease risk:A mendelian randomization study[J].Ann Neurol,2020,87(1):30-39.[20]Maseda D,Ricciotti E,Crofford LJ.Prostaglandin regulation of T cell biology[J].Pharmacol Res,2019,149(10):104456-104468.[21]Lim SA,Su W,Chapman NM,et al.Lipid metabolism in T cell signaling and function[J].Nat Chem Biol, 2022,18(5):470-481.[22]Arbore G,West EE,Spolski R,et al.T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells[J].Science,2016,352(6292):1210-1236.[23]Ryu H,Kim J,Kim D,et al.Cellular and Molecular Links between Autoimmunity and Lipid Metabolism[J].Mol Cells,2019,42(11):747-754.[24]Ji X,Wu L,Marion T,et al.Lipid metabolism in regulation of B cell development and autoimmunity[J].Cytokine Growth Factor Rev,2023,73(5):40-51.[25]Zhang J,Xiao Y,Hu J,et al.Lipid metabolism in type 1 diabetes mellitus:Pathogenetic and therapeutic implications[J].Front Immunol,2022,13:999108-999122.[26]Lei Q,Yang J,Li L,et al.Lipid metabolism and rheumatoid arthritis[J].Front Immunol,2023,14:1190607-1190621.[27]Jo Y,DeBose-Boyd RA.Post-Translational Regulation of HMG CoA Reductase[J].Cold Spring Harb Perspect Biol,2022,14(12):a041253.[28]闫雯,张小珍,齐晓明,等.RTKN2、LDLR、APOB和APOC1基因多态性与类风湿性关节炎的相关性[J].中国免疫学杂志,2018,34(11):1697-1701.[29]Berthelot JM,Jamin C,Amrouche K,et al.Regulatory B cells play a key role in immune system balance[J].Joint Bone Spine,2013,80(1):18-22.

更新日期/Last Update: 1900-01-01